Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
This study will compare mometasone nasal spray to placebo in treating the nasal and asthma
 symptoms experienced by participants with seasonal allergic rhinitis (SAR) and concomitant
 asthma.
Inclusion Criteria:

 -  Have at least a two-year history of seasonal allergic rhinitis and an increase in
 asthma symptoms associated with the allergy season under study

 -  Demonstrate an increase in absolute FEV 1 less than 12%, with an absolute volume
 increase of at least 200 ml, after reversibility testing within the past 12 months

 -  Is skin test positive (skin prick test with a wheal diameter at least 3 mm larger than
 the diluent control or intradermal testing with the wheal diameter at least 7 mm
 larger than diluent control) at screening, or within 12 months prior to the screening
 visit, to a seasonal allergen (which may include seasonal molds) prevalent during the
 study period.

 -  Female participants of childbearing potential use a medically accepted method of birth
 control and agree to continue its use during the study or be surgically sterilized
 (eg, hysterectomy or tubal ligation). Females who are not sexually active at time of
 study agree and consent to use a medically acceptable method of birth control should
 they become sexually active while participating in the study.

 Exclusion Criteria:

 -  Female participants who are pregnant, intend to become pregnant during the duration of
 the study, or are nursing.

 -  Have asthma symptoms and require chronic use of inhaled or systemic corticosteroids.

 -  Have current or historical frequent (2 or more episodes per year for the past 2
 years), clinically significant sinusitis or chronic purulent postnasal drip.

 -  Have recent nasal septum ulcers, nasal surgery or nasal trauma, which should not be
 included until healing occurs.

 -  Have rhinitis medicamentosa or chronic obstructive pulmonary disease (COPD).

 -  Have an upper or lower respiratory tract or sinus infection that requires antibiotic
 therapy, or have a viral upper or lower respiratory infection.

 -  Have nasal structural abnormalities, including large nasal polyps and marked septum
 deviation, that significantly interferes with nasal air flow.

 -  Are dependent on nasal topical antihistamines, or nasal steroids.

 -  On immunotherapy (desensitization therapy) and will receive an increase in dose during
 the study; participants who will receive desensitization treatment within 24 hours
 prior to a study visit.

 -  Is a participant who smokes, or is an ex-smoker who has smoked within the previous six
 months.

 -  Is an investigator, study staff member, or family member involved with this study.

 -  Has active or quiescent tuberculosis infection of the respiratory tract, untreated
 fungal, bacterial, or systemic viral infections, or herpes simplex.

 -  Is a participant whose ability to provide informed consent is compromised.

 -  Has a history of non-compliance with medications or treatment protocols.

 -  Is morbidly obese (BMI >35).

 -  Is a night-shift worker or does not have a standard asleep at night/awake during the
 day cycle.

 -  Has any history of life-threatening asthma attacks or is treated in the emergency room
 or admitted to the hospital for asthma control within the previous 3 months or more
 than once in the previous 6 months